Detalhe da pesquisa
1.
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
Proc Natl Acad Sci U S A
; 118(13)2021 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762304
2.
Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
bioRxiv
; 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712286
3.
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cell Rep
; 40(4): 111095, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905710
4.
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
Cancer Res Commun
; 2(9): 1061-1074, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36506869
5.
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Cell Death Dis
; 12(2): 179, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33589591
6.
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Mol Cancer Ther
; 20(10): 1868-1879, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34315769
7.
MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis.
Cancer Res
; 81(7): 1896-1908, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483374
8.
Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma.
Mol Cancer Ther
; 20(8): 1400-1411, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088831
9.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Sci Transl Med
; 10(441)2018 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769286
10.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Cancer Discov
; 4(2): 232-45, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24356096
11.
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Cancer Res
; 73(19): 6013-23, 2013 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23918797
12.
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
Cancer Res
; 73(20): 6346-58, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23966295